Vapotherm Inc

Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. Its products include Precision Flow, Precision Flow Heliox, Oxygen Assist Module, Nitric Oxidie Disposable Patient Circuit, Tracheostomy Adapter, and Aerogen Adapter. The company was founded by William F. Niland, Jun Cortez, and William Cirksena in 1998 and is headquartered in Exeter, NH.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EXETER, N.H. , June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.

Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

EXETER, N.H. , May 9, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2024 financial results and related highlights.

Vapotherm Reports First Quarter 2024 Financial Results

Partnership enables Vapotherm to build a robust and secure solution 80% faster than the standard development timeline to meet data visualization and device management goals for HVT® 2.0 and future Home system SAN FRANCISCO , March 20, 2024 /PRNewswire/ --  Onymos , developer of the world's first Features-as-a-Service platform, and Vapotherm, Inc.  (OTCQX: VAPO), ("Vapotherm"), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership. This partnership will help Vapotherm create a unique respiratory digital platform to meet its data visualization and device management goals for the Vapotherm HVT® 2.0 system in the acute care space as well as for future products in the home.

Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)

EXETER, N.H. , March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.

Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE

EXETER, N.H. , March 6, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced that David Yamane, MD was awarded the Star Research Award by the Society for Critical Care Medicine (SCCM) at the 2024 Critical Care Congress.

Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exa

EXETER, N.H. , Feb. 29, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, is pleased to announce the regulatory approval of the HVT 2.0 system in Brazil.

Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market

EXETER, N.H. , Feb. 22, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2023 financial results and related highlights.

Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results

EXETER, N.H. , Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately.

Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the “Company”) — ticker symbol VAPO — from the NYSE. Trading in the Company's common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company's common stock pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company had.

NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)

EXETER, N.H. , Dec. 11, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock Exchange ("NYSE") and its filing of an application to have its common stock quoted on the OTCQX Marketplace ("OTCQX").

Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX

EXETER, N.H. , Nov. 28, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress is excited to announce the participation of over 8,000 clinicians in interactive, digital based, evidence based education focused on a variety of respiratory clinical topics.

Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month

Vapotherm, Inc. (NYSE:VAPO ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Dorota Mckay - VP and CAO Joe Army - President and CEO John Landry - SVP and CFO Conference Call Participants Macauley Kilbane - William Blair Marie Thibault - BTIG Operator Good afternoon, and welcome to Vapotherm's Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn today's conference over to Dorota Mckay, Vapotherm's Vice President and Chief Accounting Officer.

Vapotherm, Inc. (VAPO) Q3 2023 Earnings Call Transcript

EXETER, N.H. , Nov. 8, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2023 financial results and related highlights.

Vapotherm Reports Third Quarter 2023 Financial Results

Ascent Solar Technologies Inc

Ford Motor Company

Federal Reserve officials kept current interest rate levels unchanged on Wednesday. Investors and economists will be diligently scrutinizing any hints and clues offered during this meeting, specifically regarding the long-term stability of rates and whether central bankers still view future increases as necessary in the coming months.

3 Stocks Set to Rocket When the Bears Get Short-Squeezed

EXETER, N.H. , Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.

Vapotherm To Report Third Quarter 2023 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the online publication of “Validation of Human Upper Computational Fluid Dynamics Model for Turbulent Mixing” in the Journal of Fluid Dynamics. The full article will be published in the Decembe.

Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the presentation of an Investigator-initiated clinical trial, “High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled tr.

Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children

Vapotherm, Inc. (NYSE:VAPO ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Mark Klausner - ICR Westwicke, IR Joe Army - President and CEO John Landry - SVP and CFO Conference Call Participants Jon Young - Canaccord Margaret Kaczor - William Blair Operator Thank you for standing by. My name is Greg, and I will be your conference operator today.

Vapotherm, Inc. (VAPO) Q2 2023 Earnings Call Transcript

Vapotherm (VAPO) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.84 per share a year ago.

Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2023 financial results. Second Quarter 2023 Summary and Highlights Net revenue for the second quarter of 2023 was $16.0 million, an increase of 23.6% as compared to the second quarter of 2022 Disposables revenue increased by 38.1% as compared to the second quarter of 2022 due to recovery of customer demand post-COVID Capital revenue increased by 42.0% as compared to the se.

Vapotherm Reports Second Quarter 2023 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-.

Vapotherm To Report Second Quarter 2023 Financial Results

Vapotherm, Inc. (NYSE:VAPO ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Mark Klausner - ICR Westwicke, IR Joe Army - President and CEO John Landry - Senior Vice President and CFO Conference Call Participants Margaret Kaczor - William Blair Zachary Day - Canaccord Genuity Jason Bednar - Piper Sandler Sam Eiber - BTIG Operator Good afternoon, and welcome to the Vapotherm, Inc. First Quarter 2023 Financial Results Conference Call. [Operator Instructions] I will now turn the conference over to Mark Klausner.

Vapotherm, Inc. (VAPO) Q1 2023 Earnings Call Transcript

Vapotherm (VAPO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.87 per share a year ago.

Vapotherm (VAPO) Reports Q1 Loss, Lags Revenue Estimates

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first q.

Vapotherm Reports First Quarter 2023 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-27.

News for Vapotherm Inc Stock (VAPO)